Click Here to return To Results

 

Clinical Follow-Up and Immunogenetic Studies of 32 Patients with Eosinophilia-Myalgia Syndrome Lancet 337:1071-1074, Kaufman,L.D.,et al, 1991 See this aricle in Pubmed Article Abstract 31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS)that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness.Another patient with EMS associated with L-tryptophan in 1988 was followed up for 30 months.93%of the 28 survivors from the 1989 cohort continue to have symptoms affecting 1-4 organ systems(median 3)and 3 have died,so the disorder produce considerable morbidity and mortality.The chronic sequelae most often associated with long-term disability are sclerodermatous skin thickening(54%),sensorimotor polyneuropathy(61%),proximal myopathy(36%), and severe episodic myalgias(64%).Thrombocytopenia developed in 1 patient. HLA-class II typing revealed a non-significant trend towards an association with HLA-DR4.Early therapy with corticosteroids did not seem to prevent the development of chronic manifestations.

Related Tags

(click to filter results - removes previous filter) disability,neurological eosinophilia-myalgia syndrome HLA mortality muscle pain myopathy myopathy,proximal neuropathy prognosis skin,lesions in neurologic disorders treatment of neurologic disorder

Click Here to return To Results